Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

36.14 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,112
Open 36.14
Bid (Size) 36.25 (2)
Ask (Size) 36.45 (4)
Prev. Close 36.14
Today's Range 36.14 - 36.14
52wk Range 30.04 - 67.88
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
In a rising market, the iconic growth investor is adding to positions trading well below their earlier highs. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
Exposures Artificial Intelligence Tariff
CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025. 
Via Benzinga

Performance

YTD
-12.8%
-12.8%
1 Month
+15.6%
+15.6%
3 Month
-11.0%
-11.0%
6 Month
-30.3%
-30.3%
1 Year
-32.2%
-32.2%

More News

Read More
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Via Benzinga
Exposures Product Safety
These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results
Via Benzinga
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
Via The Motley Fool
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Vertex Pharmaceuticals Topples 12% On A Series Of First-Quarter Setbacks
Via Investor's Business Daily
Topics Government Intellectual Property
Exposures Intellectual Property Political
Cathie Wood Sells Palantir Shares Worth $2.65 Million Ahead Of Earnings, Doubles Down On This Chip Giant
Via Benzinga
2 Beaten-Down Stocks With Incredible Upside Potential
Via The Motley Fool
5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years
Via The Motley Fool
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Via The Motley Fool
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox
Via Benzinga
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Exposures Economy Financial Legal
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Exposures COVID-19 Political Product Safety
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Via Investor's Business Daily
Exposures Product Safety
The Future of Healthcare: 10 Predictions For The Next Decade
Via MarketMinute
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Via The Motley Fool
Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most
Via Benzinga
Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Via The Motley Fool
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Via The Motley Fool

Frequently Asked Questions

Is CRISPR Therapeutics AG - Common Shares publicly traded?
Yes, CRISPR Therapeutics AG - Common Shares is publicly traded.
What exchange does CRISPR Therapeutics AG - Common Shares trade on?
CRISPR Therapeutics AG - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for CRISPR Therapeutics AG - Common Shares?
The ticker symbol for CRISPR Therapeutics AG - Common Shares is CRSP on the Nasdaq Stock Market
What is the current price of CRISPR Therapeutics AG - Common Shares?
The current price of CRISPR Therapeutics AG - Common Shares is 36.14
When was CRISPR Therapeutics AG - Common Shares last traded?
The last trade of CRISPR Therapeutics AG - Common Shares was at 05/08/25 04:00 PM ET
What is the market capitalization of CRISPR Therapeutics AG - Common Shares?
The market capitalization of CRISPR Therapeutics AG - Common Shares is 2.85B
How many shares of CRISPR Therapeutics AG - Common Shares are outstanding?
CRISPR Therapeutics AG - Common Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.